Skip to main content
. Author manuscript; available in PMC: 2019 May 2.
Published in final edited form as: Phys Med Biol. 2018 May 2;63(9):095007. doi: 10.1088/1361-6560/aabb5e

Table 4.

Characteristics of patients in the validation cohort

Characteristics Validation NSCLC Cohort
Distant failure (+) Distant failure (−)
Age, years
 mean ± SD 70.9 ± 9.4 75.4 ± 10.0
 Median (range) 74.0 (55.0–85.0) 74.0 (64.0–91.0)
Ethnicity, No. (%)
 Caucasian 10 (62.5)   6 (85.8)
 Hispanic   0 (0)   1 (14.2)
 African American   6 (37.5)   0 (0)
 Asian   0 (0)   0 (0)
 Other   0 (0)   0 (0)
Clinical tumor size, mm, No. (%)
 ≤ 10   0 (0)   0 (0)
 11–30 13 (81.2)   5 (71.6)
 31–50   3 (18.8)   1 (14.2)
 51–70   0 (0)   1 (14.2)
 > 71   0 (0)   0 (0)
Histology, No. (%)
 Adenocarcinoma   9 (56.2)   4 (57.1)
 Squamous cell carcinoma   6 (37.5)   3 (42.9)
 Other   1 (6.3)   0 (0)
Stage, No. (%)
 IA 15 (93.7)   7 (100.0)
 IB   1 (6.3)   0 (0)
 IIA   0 (0)   0 (0)
 IIB   0 (0)   0 (0)
 IIIB   0 (0)   0 (0)
 IVA   0 (0)   0 (0)

NOTE. Stage in NSCLC is determined by the TNM.

Abbreviations: NSCLC, non-small cell lung cancer; SD: standard deviation.